

# Predicting diabetes – clinical, biological and genetic approaches: the D.E.S.I.R. Study

Running head: A score to predict incident diabetes in France

BEVERLEY BALKAU, PHD<sup>1</sup>  
CÉLINE LANGE, BSC<sup>1</sup>  
LEOPOLD FEZEU MD, MSC<sup>1</sup>  
TICHET JEAN, MD<sup>2</sup>  
BLANDINE DE LAUZON-GUILLAIN, PHD<sup>1,3</sup>  
SEBASTIEN CZERNICHOW, MD, PHD<sup>4</sup>  
FREDERIC FUMERON, PHD<sup>5</sup>  
PHILIPPE FROGUEL, MD, PHD<sup>6</sup>  
MARTINE VAXILLAIRE, PHD<sup>6</sup>  
STEPHANE CAUCHI, PHD<sup>6</sup>  
PIERRE DUCIMETIÈRE, PHD<sup>1</sup>  
EVELINE ESCHWÈGE, MD<sup>1</sup>

<sup>1</sup> INSERM U780-IFR69, F-94807 Villejuif; France;  
Univ Paris-Sud, F-91405 Orsay, France;

<sup>2</sup> Institut inter Régional pour la Santé, F-37520 La Riche, France;

<sup>3</sup> INSERM ERI 20, EA 4045, Institut Gustave-Roussy, F-94805 France;

<sup>4</sup> Nutritional Epidemiology Research Unit-UMR U557 INSERM; U1125 INRA; CNAM;  
Univ Paris 13; CNRH IdF, F-93017 Bobigny, France;  
Public Health Department, Avicenne Hospital (AP-HP), F-93017 Bobigny, France;

<sup>5</sup> INSERM U695, F-75877 Paris, France;

René Diderot-Paris University, F-75877 Paris, France;

<sup>6</sup> UMR8090 and Institute of Biology, F-59019 Lille, France;  
Pasteur Institute, F-59019 Lille, France;  
Lille 2 University, F-59019 Lille, France.

## **Corresponding author:**

B Balkau

INSERM U780,

16 Avenue Paul Vaillant Couturier

94807 Villejuif cedex, France

E-mail: [beverley.balkau@inserm.fr](mailto:beverley.balkau@inserm.fr)

Telephone: +33 1 45 59 51 61, Fax: +33 1 47 26 94 54

This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes.

The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at <http://diabetes.diabetesjournals.org>.

**OBJECTIVES**—To provide a simple clinical diabetes risk score; to identify characteristics which predict later diabetes using variables available in clinic, then additionally biological variables and polymorphisms.

**RESEARCH DESIGN AND METHODS**—Incident diabetes was studied in 1863 men and 1954 women, 30-65 years at baseline, by treatment or by fasting plasma glucose  $\geq 7.0$  mmol/l at 3-yearly examinations over nine years. Sex-specific logistic regression equations were used to select variables for prediction.

**RESULTS**—140 men, 63 women developed diabetes. The predictive clinical variables were: waist circumference and hypertension in both sexes; for men: smoking, for women: diabetes in the family. Discrimination, as measured by the areas under the receiver operating curves (AROC), were 0.713 for men and 0.827 for women, a little higher than for the FINDRISC score, with fewer variables in the score. Combining clinical and biological variables, the predictive equation included for men: fasting glucose, waist circumference, smoking,  $\gamma$ -glutamyltransferase; for women fasting glucose, BMI, triglycerides, diabetes in family. The number of *TCF7L2* and *IL6* deleterious alleles was predictive in both sexes, but after including the above clinical and biological variables, this variable was only predictive in women ( $p < 0.03$ ) and the AROC statistics increased only marginally.

**CONCLUSIONS**—The best clinical predictor of diabetes is adiposity, and baseline glucose is the best biological predictor. Clinical and biological predictors differed marginally between men and women. The genetic polymorphisms added little to the prediction of diabetes.

Key words: epidemiology, diabetes, incidence

A number of diabetes risk scores have been developed to detect those who *should be screened* for diabetes (1). In the Data from an Epidemiological Study on the Insulin Resistance Syndrome (D.E.S.I.R.) cohort we have already studied the anthropometric variables *associated* with diabetic levels of fasting glucose and found that BMI, waist circumference and waist-hip ratio were equally useful in their identification of individuals with undiagnosed diabetes (2).

The first score to identify lifestyle and clinical parameters *predictive of later* diabetes was developed by Lindström and Tuomilehto (3), from a population-based sample of people who responded to questionnaires in 1987; 10-year incident diabetes was identified from a registry of diabetes treatment. A similar Finnish Diabetes Risk Score, FINDRISC, was used in a cross sectional study (4). In the American ARIC study, and in a Thai population, predictive risk factors were also identified, diabetes was defined by treatment or diabetic levels of fasting and 2 hr glucose from an oral glucose tolerance test (OGTT)(5,6). More recently Simmons published a score from the EPIC-Norfolk study, with incident diabetes defined by clinical identification of diabetes or an HbA1c > 7% (7), which included dietary factors and physical activity. Finally, dietary and other non-invasive factors associated with 5-year incident, self-reported cases of diabetes, were identified in the large EPIC-Potsdam study (8).

In the San Antonio Study, Stern published a score based on prospective clinical and biological data (9). In the Framingham cohort, four scores were proposed, a clinical score and three scores with both clinical and biological factors with incident diabetes identified at follow up by diabetic treatment and/or fasting glucose levels (10).

Other studies on diabetes risk factors include one in French men with impaired fasting glucose (6.1-6.9 mmol/l), which identified lifestyle, clinical and biological factors predictive of diabetes (11).

As risk scores cannot always be generalized from one country to another (12,13), the aim of this study was to describe sex-specific lifestyle and clinical diabetes risk factors in a French population followed over 9 years, which would aid in identifying those at risk for *incident* diabetes. The additional aims were to study the impact of biological factors and genetic polymorphisms in predicting diabetes.

## **RESEARCH DESIGN AND METHODS**

### **Study population**

The study population was men and women aged 30–64 years, who participated in the 9-year follow-up study, D.E.S.I.R. Participants were recruited from volunteers offered periodic health examinations free of charge by the French Social Security, in 10 health examinations centres in western France. All subjects signed an informed consent and the protocol was approved by an ethics committee.

Incident cases of diabetes were identified by treatment for diabetes or a fasting plasma glucose  $\geq 7.0$  mmol/l, at one of the three-yearly examinations, after exclusion of individuals with diabetes at baseline and those with unknown diabetic status at the 9-year examination; the 1863 men and 1954 women who had glucose, BMI and waist circumference available at baseline were studied.

## Measures

Two measures of blood pressure, using a mercury sphygmomanometer, and of heart rate were taken in a supine position after 5 minutes rest; mean values were used. Weight and height were measured in lightly clad participants, and BMI calculated. The waist circumference, the smallest circumference between the lower ribs and the iliac crests, was also measured.

The examining physician noted the family history of diabetes and menopausal status in a clinical questionnaire; treatment for diabetes, hypertension and lipids were recorded. Hypertension was defined by systolic/diastolic blood pressures of at least 140/90 mmHg or being on antihypertensive medication. Smoking habits, alcohol consumption (glasses per day of wine, beer, cider, spirits) and degree of physical activity (at home, at work and sport) were assessed using a self-administered questionnaire.

All biochemical measurements were from one of four health-centre laboratories located in France at Blois, Chartres, La Riche or Orléans. Fasting plasma glucose, measured by the glucose-oxidase method, was applied to fluoro-oxalated plasma using a Technicon RA100 (Bayer Diagnostics, Puteaux, France) or a Specific or a Delta device (Konelab, Evry, France). Total cholesterol, HDL-cholesterol, triglycerides, alanine aminotransferase (ALT),  $\gamma$ -glutamyltransferase (GGT), and creatinine were assayed by DAX 24 (Bayer Diagnostics, Puteaux, France) or KONE (Evry, France). Insulin was quantified by micro particle enzyme immunoassay with an automated analyzer IMX (Abbott, Rungis, France). White cell counts were determined by a Technicon H\* or a Technicon H3RTX (Bayer Diagnostics, Puteaux, France) or a JT2 (Beckman/Coulter, Roissy, France) or an Argos (ABX, Montpellier, France). The inter-laboratory variability was assessed monthly on normal and pathological values for each biologic variable.

Single nucleotide polymorphism (SNP) genotyping was performed with the SNPlex™ Technology (Applied Biosystems, Foster City, CA) based on the Oligonucleotide

Ligation Assay (OLA) combined with multiplex PCR target amplification (<http://www.appliedbiosystems.com>) (14).

### **Statistical methods**

Statistical analysis used SAS Version 9.1 (SAS Institute Inc. Cary, NC USA). Alcohol intake, BMI, fasting glucose, insulin, ALT, GGT, triglycerides and white blood cell count were log-transformed because of their skewed distributions.

Characteristics of men and women with and without incident diabetes are shown by means (SDs) or numbers (percentages) and compared by t- or  $\chi^2$ -tests, or by linear regression for the polymorphisms with additive models. The logistic model was used to test for interactions with sex and *P-values* are reported; significant interactions ( $P < 0.01$ ) provided the rationale for sex-specific models.

The linearity of continuous parameters in logistic analyses was studied by adding a squared term and comparing nested models by likelihood ratio tests; all variables were *linearly* related with the logit of diabetes incidence excepting fasting glucose (log-transformed); in the models, glucose (log) was centred by subtracting its mean, and its square was systematically included.

Parsimonious logistic regression models were selected using forwards, backwards as well as BEST model selection criteria using all parameters; the Hosmer-Lemeshow goodness-of-fit test was the principal criteria for selection of a model. Interactions with sex were tested. The area under the receiver operating characteristic sensitivity-specificity curve (AROC) quantified the discrimination between diabetic and non-diabetic participants. Bootstrap sampling was used to validate the choice of variables in the models, with 1000 samples of the same sizes as the study populations. The choice of variables was also validated in the Cox model.

To derive a simple *clinical* score from the clinical equations, we used the beta coefficients from the logistic regression analysis; for waist circumference four groups were defined, linearly, from the approximate sex-specific quartiles. The score was validated in two French cohorts, E3N and SU.VI.MAX (15,16) (On-line figure 1). The first study identified incident diabetes by self-questionnaire or treatment reimbursement, the second by fasting glucose or treatment.

Four polymorphisms were chosen for study (*Glucokinase: GCK-30 G/A rs1799884, Interleukine 6: IL6-174 G/C rs1800795, Kir6.2: KCNJ11 E23K rs5219 and TCF7L2 rs7903146*) following previous analyses in this population (14). Additive models discriminated best between diabetic and non-diabetic people. For the two polymorphisms found to be the most related with incident diabetes (IL6, TCF7L2), the number of deleterious alleles (as a continuous variable) was calculated, and added as a variable to the (clinical + biological) equations chosen above. As this analysis aimed to determine those who should be screened for diabetes, we have analysed all individuals, and have not excluded those born outside of mainland France. This analysis was on a smaller population (1655 men, 1740 women) where these two polymorphisms were available.

We compared our clinical risk score with the FINDRISC score (3) using the AROC-statistic; FINDRISC includes age, BMI, waist circumference, anti-hypertensive medication, physical activity, previously known high glucose and daily consumption of vegetables, fruits or berries; we were not able to include latter two items. Our (clinical + biological) equation was compared with the Stern equation, including age, sex, fasting glucose, systolic blood pressure, HDL-cholesterol, BMI, diabetes in the family; we did not include the factor for coding Mexican Americans (9).

## RESULTS

In the D.E.S.I.R. population, 140 men and 63 women had incident diabetes

### Clinical predictors of incident diabetes

All of the clinical variables showed similar relations with incident diabetes in both men and women with the exception of diabetes in the family: noted for 43% of women with incident diabetes, 19% in those without; for men 20% and 18% respectively ( $P$  sex-interaction=0.003) (Table 1).

The first most predictive variable was waist circumference, closely followed by BMI, in both genders. The selected model in men included waist circumference, smoking and hypertension; for women, waist circumference, diabetes in the family, and hypertension (Table 2). These models showed a good fit (Hosmer-Lemeshow  $P$ -values: 0.7; 0.6, men; women respectively) and discriminated well the diabetic and non-diabetic populations (AROC 0.733; 0.839). In the bootstrap samples these were the most frequently chosen models. These variables were also chosen by the Cox modeling.

### Clinical risk score

From the above equations, clinical risk scores were derived (Table 3). These scores showed a good fit (Hosmer-Lemeshow  $P$ -values: 0.8; 0.9 men women respectively) and the discrimination was similar to the more exact equation with continuous values of waist circumference.

The ROC curves for the clinical equation and for the simplified clinical score are shown for men and women (Fig. 1A); the D.E.S.I.R. scores with three variables had AROC values slightly higher than for the five-variable FINDRISC score. The score predicted diabetes in the two French cohorts, with AROCS similar to those from D.E.S.I.R. (On-line Figure).

### ***Biologic predictors of incident diabetes***

Fasting glucose was by far the factor the most predictive of incident diabetes with a no difference in its effect between men and women ( $P$  interaction = 0.1) (Table 1). Predictive factors differing between genders were triglycerides and HDL-cholesterol: both had a slightly stronger relation in women ( $P$  sex-interaction = 0.006, 0.008 respectively).

### ***Clinical+Biological predictors of incident diabetes***

Fasting glucose (including its squared term) was the most predictive of all factors. After adjustment for fasting glucose, waist circumference was more predictive than BMI in men, but BMI was more predictive than waist in women (Table 2). In men, the predicting equation included fasting glucose, smoking status, waist circumference and GGT; for women, fasting glucose, BMI, diabetes in the family and triglycerides. The same variables were chosen by Cox modelling with five predictive variables.

Our (clinical + biological) equation was simpler than the Stern equation with only four variables, and discriminated similarly, incident diabetic individuals (Fig. 1B).

### ***Genetic polymorphisms as predictors of incident diabetes***

None of the four polymorphisms was significantly related with incident diabetes in either men or women, using either the three genotypes or recessive, dominant or additive models of inheritance (On-line Table). There was no interaction with sex, and combining men and women, TCF7L2 and IL6 were significantly related with incident diabetes using additive models ( $P < 0.01$ , 0.03 respectively). In comparison to individuals with no deleterious alleles, those with four deleterious alleles had an odds ratio of incident diabetes of 3.60 (1.09-11.9) in men and 3.22 (0.62-16.5) in women. The number of

deleterious alleles was associated with incident diabetes, in both men and women ( $P < 0.008$ ; 0.03 respectively) (Table 1).

Including the total number of deleterious alleles in the above determined (clinical + biological) equations, they showed an adequate fit but changed little the AROC (Table 2).

## DISCUSSION

Both the clinical and the (clinical+biological) equations are able to predict diabetes incidence over a 9-year follow-up, with different variables in the equations for men and women. Age was not selected in any of the equations, but the effect of ageing would pass by other parameters such as adiposity, hypertension, glucose levels. Age was included in the equations of many (3,5,8-10) but not all of the other published studies of risk equations (7). Polymorphisms added little to these scores. As expected, the equations derived on our population performed slightly better than those derived in other populations. The clinical score performed well on two other French cohorts.

Our diabetes risk score based on clinical data, has the advantage that it is simple, and requires only three parameters. Given a larger population and a higher incidence of diabetes, other parameters might have been included in the equations, but the discrimination and model fit may not be greatly improved.

BMI and waist circumference had similarly predictive values in both men and women; once one was included, the other no longer entered the model. Similar comments can be made for GGT and ALT.

In contrast to other scores, we have studied men and women separately and found that the predictive equations differ. In both sexes, waist circumference was the clinical factor the most related with incident diabetes, then in men smoking, which was more common in men than women; diabetes in the family was a predictive factor only in the

women. Hypertension was predictive of diabetes in both sexes, a factor often present before diabetes (17). Smoking is recognised as a risk factor for diabetes, with a higher risk for the heavy smokers in comparison to the lighter and former smokers (18). Our observation that more diabetic women than men have diabetes in the family, is probably due to women being more aware of their family diabetes. In the multivariate equations physical activity was not predictive – this could be because of its negative correlation with waist circumference and hypertension and perhaps because our questions on self-reported physical activity were not sufficiently precise, in comparison to other data such as waist circumference and hypertension. Other studies have indeed included physical activity in their multivariate equations (3,7,8).

The overriding biological factor predictive of diabetes was the baseline glucose level. In the (clinical+biological) equation in men, the GGT also entered the equation, in women the triglycerides concentration. We have already shown that GGT is predictive of incident diabetes in this cohort, for both genders (19), and others have shown that triglycerides are predictive (5,10).

The polymorphisms studied provided little towards predicting diabetes: for the 1655 men and 1740 women with these data available, the Hosmer-Lemeshow tests showed a poorer fit for men when the genetic data was included, but identical AROCs. Of note, in women, the coefficient for the parameter: diabetes in the family, was only reduced from 0.80 to 0.75 when genetic parameters were included, indicating there are probably other genetic factors involved. A large panel of SNPs may be needed to out-perform even simple clinical parameters.

One of the limitations is that we have not been able to include the 2-hour glucose concentration in our definition of diabetes: in France screening of diabetes with fasting glucose is common, so our score is appropriate in the local situation. A further limitation is that score is only for people between 30 and 65 years

The simplest clinical parameter for identifying those at risk of diabetes is adiposity – and taken alone, either waist circumference or BMI did equally well in predicting later diabetes during the nine year follow up. The addition of hypertension, and smoking in men, triglycerides in women provides a clinical score which discriminates well.

## ACKNOWLEDGMENTS

The D.E.S.I.R. study has been supported by INSERM contracts with CNAMTS, Lilly, Novartis Pharma and Sanofi-Aventis; by INSERM (Réseaux en Santé Publique, Interactions entre les déterminants de la santé), the Association Diabète Risque Vasculaire, the Fédération Française de Cardiologie, La Fondation de France, ALFEDIAM, ONIVINS, Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Santé, Novo Nordisk, Pierre Fabre, Roche, Topcon.

The D.E.S.I.R. Study Group. INSERM U780: B. Balkau, P. Ducimetière, E. Eschwège; INSERM U367: F. Alhenc-Gelas; CHU D'Angers: Y. Gallois, A. Girault; Bichat Hospital: F. Fumeron, M. Marre; CNRS UMR8090, LILLE: P. Froguel; Centres d'Examens de Santé: Alençon, Angers, Caen, Chateauroux, Cholet, Le Mans, Tours; Institute de Recherche Médecine Générale: J. Cogneau; General practitioners of the region; Institute inter-Regional pour la Santé: C. Born, E. Caces, M. Cailleau, J.G. Moreau, F. Rakotozafy, J. Tichet, S. Vol.

We thank FRANCOISE CLAVEL-CHAPELON AND SERGE HERCBERG for making their data available from the E3N and SU.VI.MAX studies respectively for the validation of our clinical risk score, and Sylviane Vol and Gaëlle Gusto for their careful reading and criticisms of the manuscript.

## References

1. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R, John A: Screening for type 2 diabetes: literature review and economic modelling. *Health Technol Assess* 11:1-125, 2007
2. Balkau B, Sapinho D, Petrella A, Mhamdi L, Cailleau M, Arondel D, Charles MA; D.E.S.I.R. Study Group: Prescreening tools for diabetes and obesity- BMI, waist and waist hip ratio. The D.E.S.I.R. Study. *Eur J Clin Nutr* 60:295-304, 2006
3. Lindström J, Tuomilehto J: The diabetes risk score: a practical tool to predict type 2 diabetes risk. *Diabetes Care* 26:725-731, 2003
4. Saaristo T, Peltonen M, Lindström J, Saarikoski L, Sundvall J, Eriksson JG, Tuomilehto J: Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. *Diab Vasc Dis Res* 2:67-72, 2005
5. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, Folsom AR, Chambless LE; The Atherosclerosis Risk in Communities Investigators: Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. *Diabetes Care* 28:2013-2018, 2005
6. Aekplakorn W, Bunnag P, Woodward M, Sritara P, Cheepudomwit S, Yamwong S, Yipintsoi T, Rajatanavin R : A risk score for predicting incident diabetes in the Thai population. *Diabetes Care* 29:1872-1877, 2006
7. Simmons RK, Harding AH, Wareham NJ, Griffin SJ; EPIC-Norfolk Project Team : Do simple questions about diet and physical activity help to identify those at risk of Type 2 diabetes? *Diabet Med* 24:830-835, 2007
8. Schulze MB, Hoffmann K, Boeing H, Linseisen J, Rohrmann S, Mohlig M, Pfeiffer AF, Spranger J, Thamer C, Häring HU, Fritsche A, Joost HG: An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. *Diabetes Care* 30:510-515, 2007

9. Stern MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? *Ann Intern Med* 136:575-581, 2002
10. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr: Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. *Arch Intern Med* 167:1068-1074, 2007
11. Lecomte P, Vol S, Caces E, Born C, Chabrolle C, Lasfargues G, Halimi JM, Tichet J: Five-year predictive factors of type 2 diabetes in men with impaired fasting glucose. *Diabetes Metab* 33:140-147, 2007
12. Rathmann W, Martin S, Haastert B, Icks A, Holle R, Löwel H, Giani G; KORA Study Group: Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey 2000. *Arch Intern Med* 165:436-441, 2005
13. Glümer C, Vistisen D, Borch-Johnsen K, Colagiuri S; DETECT-2 Collaboration: Risk scores for type 2 diabetes can be applied in some populations but not all. *Diabetes Care* 29:410-414, 2006
14. Clavel-Chapelon F, van Liere MJ, Giubout C, Niravong MY, Goulard H, Le Corre C, Hoang LA, Amoyel J; Auquier A, Duauesnel E: E3N, a French cohort study on cancer risk factors. E3N Group. Etude Epidemiologique aupres de femmes de l'Education Nationale. *Eur J Cancer Prev* 6:473-478, 1997
15. Czernichow S, Couthouis A, Bertrais S, Vergnaud AC, Dauchet L, Galan P, Hercberg S: Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. *Am J Clin Nutr* 2006 84:395-399, 2006
16. Vaxillaire M, Veslot J, Dina C, Proença C, Cauchi S, Charpentier G, Tichet J, Fumeron F, Marre M, Meyre D, Balkau B, Froguel P; for the D.E.S.I.R. Study Group: Impact of Common Type 2 Diabetes Risk Polymorphisms in the D.E.S.I.R. Prospective Study. *Diabetes* 57:244-254, 2008
17. Conen D, Ridker PM, Mora S, Buring JE, Glynn RJ. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. *Eur Heart J* 28:2937-2943, 2007

18. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J: Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA* 298:2654-2664, 2007
19. André P, Balkau B, Born C, Royer B, Wilpart E, Charles MA, Eschwège E: Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. The D.E.S.I.R. Study (Data from an Epidemiological Study on the Insulin Resistance syndrome). *Diabetes Metab* 31:542-550, 2005

## Figure Legends

**Figure 1**—Receiver Operating Characteristic (ROC) curves and the AROC statistics in men and women for **A.** the D.E.S.I.R. French clinical equation, the French clinical risk score and the FINDRISC clinical score (3); **B.** the D.E.S.I.R (clinical+biological). French risk equation and the Stern risk equation (9).

**Table 1**—Clinical and biological characteristics [mean(SD) or number (%)] at baseline of men and women with and without incident diabetes during the 9 years of the D.E.S.I.R. study.

	Diabetes n=140	Men No diabetes n=1723	<i>P</i> *	Diabetes n=63	Women No diabetes n=1891	<i>P</i> *	<i>P</i> for variable	<i>P</i> interaction with sex
Age (years)	50 (9)	47 (10)	0.0001	52 (8)	47 (10)	0.0005	0.0001†	0.6
Diabetes in the family	28 (20%)	312 (18%)	0.6	27 (43%)	368 (19%)	0.0001	‡	0.003
Current smoker	52 (37%)	418 (24%)	0.0009	10 (16%)	249 (13%)	0.5	0.001†	0.3
Alcohol intake (g/day) §	34 (32)	23 (22)	0.005	8 (11)	7 (11)	0.5	0.006†	0.2
Physical activity								
Little	43 (31%)	422 (24%)		22 (35%)	465 (25%)			
Moderate	72 (51%)	911 (53%)	0.07	33 (52%)	1036 (55%)	0.04	0.03†	0.7
Intensive	25 (18%)	388 (23%)		8 (13%)	386 (20%)			
Waist circumference (cm)	96 (10)	89 (9)	0.0001	90 (12)	76 (10)	0.0001	0.0001†	0.3
BMI (kg/m <sup>2</sup> ) §	27.5 (4.0)	25.1 (3.0)	0.0001	29.2 (5.1)	23.7 (3.8)	0.0001	0.0001†	0.3
Menopause				30 (48%)	718 (38%)	0.1		
Large baby, birth weight ≥ 4 kg				16 (27%)	284 (15%)	0.02		
Hypertension	87 (62%)	678 (39%)	0.0001	39 (62%)	527 (28%)	0.0001	0.0001	0.1
Heart rate (min)	68 (10)	66 (10)	0.007	71 (11)	68 (9)	0.02	0.0005†	0.7
Treatment for lipids	20 (14%)	126 (7%)	0.004	9 (14%)	129 (7%)	0.03	0.0003†	0.9
Fasting glucose (mmol/l) §	6.05 (0.55)	5.39 (0.49)	0.0001	5.96 (0.58)	5.11 (0.46)	0.0001	0.0001†	0.1
GGT (IU/l) §	64.3 (67.2)	39.5 (38.3)	0.0001	36.4 (33.6)	21.7 (21.2)	0.0001	0.0001†	0.4
ALT (IU/l) §	41.7 (28.3)	30.3 (18.1)	0.0001	28.9 (22.2)	20.1 (13.8)	0.0001	0.0001†	0.4
Triglycerides (mmol/l) §	1.79 (1.45)	1.26 (0.80)	0.0001	1.50 (0.78)	0.93 (0.50)	0.0001	‡	0.006
HDL-cholesterol (mmol/l)	1.41 (0.37)	1.50 (0.38)	0.01	1.53 (0.34)	1.80 (0.42)	0.0001	‡	0.008
Total-cholesterol (mmol/l)	6.06 (1.05)	5.82 (0.97)	0.009	5.94 (1.04)	5.61 (0.96)	0.02	0.0001†	0.6
Creatinine (μmol/l)	91.0 (13.9)	89.1 (11.1)	0.06	77.1 (10.7)	74.1 (10.0)	0.02	0.006†	0.4
White Blood Cell count (10 <sup>9</sup> /l) §	6.9 (2.1)	6.4 (1.7)	0.002	7.3 (4.0)	6.2 (1.6)	0.0002	0.0001†	0.2
	n=135	n=1617		n=61	n=1782			
Number of TCF7L2, IL6 deleterious alleles	2.0	1.8	0.008	2.2	1.8	0.03	0.0007	0.7

\* *P*-value comparing means and percentages, by *t*- and  $\chi^2$  tests

† *P*-value for variable in logistic model with only variable and sex, as interaction not significant

‡ *P*-value for variable not given, as the interaction is significant

§ log-transformation because of a non-symmetric distributions

|| hypertension: systolic / diastolic blood pressures ≥ 140 / 90 mmHg or medication for hypertension

**Table 2**—Beta coefficients for the clinical, (clinical+biological), (clinical+biological+genetic) equations. The D.E.S.I.R. Study

<b>Men</b>						
Variable	Clinical Equation 140 diabetic men, n=1860		Clinical + Biological Equation 140 diabetic men, n=1860		Clinical + Biological + Genetic Equation 128 diabetic men, n=1655	
	beta	<i>P</i>	beta	<i>P</i>	beta	<i>P</i>
Intercept	-10.45		-10.53		10.91	
Current smoker	0.72	0.0002	0.88	0.0001	0.94	0.0001
Waist circumference (cm)	0.081	0.0001	0.060	0.0001	0.060	0.0001
Hypertension *	0.50	0.01				
Fasting glucose (mmol/l) †			10.15	0.0001	10.17	0.0001
Fasting glucose <sup>2</sup> †			24.16	0.002	22.42	0.007
GGT (IU/l) †			0.39	0.01	0.42	0.007
Number of TCF7L2, IL6 deleterious alleles					0.14	0.2
AROC-statistic	0.733		0.850		0.851	
Hosmer-Lemeshow fit test	<i>P</i> = 0.7		<i>P</i> = 0.8		<i>P</i> = 0.1	
* glucose and GGT were log-transformed						
<b>Women</b>						
Variable	Clinical Equation 63 diabetic women n=1954		Clinical + Biological Equation 63 diabetic women n=1954		Clinical + Biological + Genetic Equation 58 diabetic women, n=1740	
	beta	<i>P</i>	beta	<i>P</i>	beta	<i>P</i>
Intercept	-11.81		-18.91		-20.43	
Diabetes in the family	1.09	0.0001	0.80	0.01	0.75	0.02
Waist circumference (cm)	0.095	0.0001				
BMI (kg/m <sup>2</sup> ) †			4.38	0.0001	4.69	0.0001
Hypertension *	0.64	0.03				
Fasting glucose (mmol/l) †			9.66	0.001	9.35	0.001
Fasting glucose <sup>2</sup> †			23.89	0.06	22.39	0.08
Triglycerides (mmol/l) †			0.95	0.003	0.86	0.01
Number of TCF7L2, IL6 deleterious alleles					0.36	0.04
AROC-statistic	0.839		0.917		0.912	
Hosmer-Lemeshow fit test	<i>P</i> = 0.6		<i>P</i> = 0.9		<i>P</i> = 0.8	

\* hypertension: systolic / diastolic blood pressures  $\geq$  140 / 90 mmHg or medication for hypertension

† fasting glucose, GGT, BMI and triglycerides were log-transformed

**Table 3**— A clinical diabetes risk score of 5 confers a more than 30% chance of diabetes in the following 9 years, The D.E.S.I.R. Study

Men			Women		
		Scores to sum			Scores to sum
Waist circumference	< 80 cm	0	Waist circumference (cm)	< 70 cm	0
	80-89 cm	1		70-79 cm	1
	90-99 cm	2		80-89 cm	2
	≥ 100 cm	3		≥ 90 cm	3
Current Smoker - yes		1	Diabetes in the family - yes		1
Hypertension* - yes		1	Hypertension - yes		1
AROC-statistic		0.713	AROC-statistic		0.827
Hosmer-Lemeshow fit test		<i>P</i> = 0.8	Hosmer-Lemeshow fit test		<i>P</i> = 0.9

\* hypertension: systolic / diastolic blood pressures ≥ 140 / 90 mmHg or medication for hypertension